AG
GLMD icon

Advisor Group’s Galmed Pharmaceuticals GLMD Stock Holding History

Advisor Group’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Hold
0
– – – 5356
2019
Q3 		– Hold
0
– – – 5313
2018
Q3 		– Sell
-1
Closed -$14K – 5142
2018
Q2 		$14K Buy
+1
New +$11.6K ﹤0.01% 3906

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $131M AUM 35.16% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
RCG
Rock Creek Group Washington, District of Columbia $994M AUM 11.29% 1-Year Est. Return

Advisor Group's GLMD Position: Q4 2019 in Review

Advisor Group held its Galmed Pharmaceuticals (GLMD) position steady in Q4 2019 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5356.

Advisor Group first reported a position in GLMD in Q2 2018 and has held it in 1 quarter since. The position peaked at $14K in Q2 2018. 28 funds tracked by Wall St. Rank hold GLMD as of Q4 2019.

  • Advisor Group held 0 shares of Galmed Pharmaceuticals worth $0 as of Q4 2019.
  • Advisor Group left its Galmed Pharmaceuticals share count unchanged in Q4 2019.
  • Galmed Pharmaceuticals made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5356 holding.
  • Advisor Group first reported a position in Galmed Pharmaceuticals in Q2 2018 and has held it in 1 quarter since.
  • Advisor Group's Galmed Pharmaceuticals position peaked at $14K in Q2 2018.
  • 28 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.